Menu
We’re focused on specialty pharmaceutical brands that aim to deliver enhancements over standard medicines, such as the way in which medicines are delivered, to help make the treatment experience better for all involved. We think beyond the expected, delivering high-quality oncology, immunology, and critical care therapies—with a humanizing twist.
We’re always analyzing the marketplace, holistically examining treatment options, and considering how we can take a product that’s currently available and fine tune it to deliver it in a more cost-effective or consumer-friendly way.
We want to be recognized as a company that does it right. The right approach, the right improvements, the right medicines delivered in the right way at the right time. It’s the foundation of who we are. It’s our culture. And it has been this way since the formation of our parent company, Intas Pharmaceuticals, in 1976.
As one of the pioneers and market leaders of biosimilars, having launched its first product in India in 2004, Intas has long been ahead of the game in this space. Backed by the foundation they have built, we are able to maintain an entrepreneurial mindset with the resources and manufacturing capabilities to bring our insights and ideas to fruition.
Pharmaceutical company with rapid decision-making and a focus on long-term returns
~30% volume share of major chemotherapy molecules in key geographies
Developing, manufacturing, and marketing biologics for more than 20 years with one of India’s largest r-protein fermentation capacities
From development, clinical research, manufacturing, regulatory, commercial and fully developed back office
$2.5B global sales FY2022
Sales derived from 85+ countries with ~60% from EU and U.S.
19,000+ employees including 7,500+ commercial staff globally
14,000 MAs in a myriad of dose forms including biologics and brands
560+ scientists involved in product development across the globe
Portfolio and pipeline comprising 50+ brands by 2024
Partner of choice for leading developers wanting to access full infrastructure in major markets
Ranked number two in India, expanding strong foundations to become a leading differentiated products player in the global animal health market
Leaders in fractionation in India and looking to expand in the global market in the near term
Establishing a Center of Excellence with state-of-the-art facilities for supporting R&D activities in biosimilars, ADCs, and novel biologics
Over $450M investment in sites and new initiatives
Chrys has worked in the industry since the inception of biosimilars. While he initially sought to preserve the uniqueness and innovation of originator biologic drugs, Chrys’ mindset progressed to the point where he instead began working to establish the legitimacy, efficacy, and potential financial benefit of biosimilars. And his evolved thinking and vision for biosimilars is mirrored in Accord BioPharma’s approach, our senior leaders, and everyone at the company.
Our corporate foundation is built on three pillars: enhance the patient experience, enhance the customer experience, and provide value to the entire healthcare system. Biosimilars are just one way we’re achieving that vision.
Biosimilars are uniquely positioned to provide value to each key stakeholder in our healthcare system. But there are several key considerations that these groups—namely, patients, prescribers, payers, and specialty pharmacies—must be aware of to help biosimilars unlock their full potential. If all involved groups can understand the potential value of these medicines, recognize and ignore misinformation, and educate each other on what actions they would need to undertake, everyone can benefit from the savings biosimilars create.1
Just how much could that total? The biosimilars that have entered the market have launched with initial list prices anywhere from 15% to 35% lower than their biologic competitors.2 And a recent study from the Association for Accessible Medicines reveals generic and biosimilar drugs together generated a record $408 billion in savings for America’s patients and healthcare system in 2022.3 Increased adoption of biosimilars could significantly increase savings.
Want to know more about biosimilars and how they’re made? Visit our Understanding Biosimilars page to get answers to some of the most common biosimilars questions.
For more on the impact biosimilars can create and Accord BioPharma’s story, visit the following pages:
1. Biosimilars in the United States 2023-2027. IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2023-2027. Published January 31, 2023.
2. Decreasing drug costs through generics and Biosimilars. National Conference of State Legislatures. https://www.ncsl.org/health/decreasing-drug-costs-through-generics-and-biosimilars. Published January 21, 2022.
3. 2023 U.S. Generic and Biosimilar Medicines Savings Report. Association for Accessible Medicines. September 2023. https://accessiblemeds.org/sites/default/files/2023-09/2023-Savings-Report-Social-Toolkit.pdf.
Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.
CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction and spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.
Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.
Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and be managed according to current clinical practice.
Androgen deprivation therapy may prolong the QT/QTc interval. Consider periodic monitoring of electrocardiograms and electrolytes.
Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.
Monitor serum levels of testosterone following injection of CAMCEVI.
Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.
The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.
CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.
Click here for full Prescribing Information.
©2024 Accord BioPharma, Inc. All rights reserved WS-ABI-2200001
